Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Status:
Recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The I-MAT trial is a randomised, placebo-controlled, phase II trial of adjuvant Avelumab in
patients with stage I-III Merkel cell carcinoma aiming to explore the efficacy of avelumab as
adjuvant immunotherapy.